Please login to the form below

Not currently logged in

Novartis wins key adjuvant Taf/Mek approval in Europe

Ex-GSK duo on course for first blockbuster year

Novartis’ cancer combination Tafinlar and Mekinist has been approved by the EMA for adjuvant treatment of advanced melanoma in order to prevent disease recurrence.

The new indication – the third for the BRAF/MEK inhibitor combination – is an important one for Novartis as it faces increasing competition in the melanoma market from immuno-oncology drugs like Bristol-Myers Squibb’s Opdivo and Merck & Co/MSD’s Keytruda.

The EMA has approved Tafinlar (dabrafenib) and Mekinist (trametinib) for the adjuvant (post-surgery) treatment of stage III melanoma patients with BRAF V600 mutations, following in the footsteps of the US FDA which gave a green light to this indication earlier this year.

Approval is based on the 870-patient COMBI-AD study, which showed that patients who received the combination treatment had a statistically significant improvement in relapse-free survival (RFS) compared with those on placebo.

All told, 38% of patients on the Taf/Mek combination had a relapse or died after the primary data cut-off point of more than two and a half years, compared to 57% of the control group, and that benefit has been maintained beyond three years in later analyses.

Novartis acquired Tafinlar and Mekinist as part of its asset-swap deal with GlaxoSmithKline (GSK) in 2015, and since taking over the drugs has grown sales considerably thanks to additional approvals including a go-ahead last year in BRAF V600-postitive non-small cell lung cancer (NSCLC). Sales in the first half of this year rose by a third to $551m, setting it on course for its first blockbuster year.

Vas Narasimhan

Novartis chief executive Vas Narasimhan said during the company’s second-quarter results call that “treating patients earlier in the adjuvant setting will enable us to continue to drive Mekinist and Tafinlar… particularly given the competition that of course has come up in the class.”

Taf/Mek competes directly with Roche's Zelboraf (vemurafenib) and Cotellic (cobimetinib) combination in melanoma, but has been outselling its rival, particularly after Roche’s duo failed to hit the mark in an adjuvant melanoma study last year.

PD-1 inhibitors Opdivo and Keytruda, which have been steadily moving up the treatment pathway in melanoma, have also emerged as a competitive threat to Taf/Mek, although there is now talk of using the cancer immunotherapies and small-molecule BRAF/MEK pair in combination.

BMS’ drug picked up an FDA approval for adjuvant melanoma therapy last December based on the results of the phase III CheckMate-238 trial, and was recommended for approval in that indication in the EU in June. Meanwhile, Merck filed an application for Keytruda in the US in June as an adjuvant therapy based on the KEYNOTE-054 trial.

Article by
Phil Taylor

29th August 2018

From: Marketing



Featured jobs

Subscribe to our email news alerts


Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

Playing Mind Games
To give a brief strong direction, we need to ascertain how the brand intends to win attention, how it will engage, what its call to action will be and how...
PM Society Digital Award Finalists
P&P are shortlisted for the ‘Craft in Film’ category at this year’s PM Society Digital Awards...
The Exhibition Hall: Past, Present and Future
As I sit here at another pharma conference, I start to reflect on how they have changed over the years....